Therapeutic peptides, as well as broader biologics and biotherapeutics, are rapidly reshaping the treatment landscape for chronic diseases, offering precision, potency and specificity that small molecules often can’t match. Among peptide-based therapeutics, such as, Glucagon-Like Peptide-1 (GLP-1) receptor agonists – including semaglutide and liraglutide – have emerged as game changers in managing type 2 diabetes, obesity and cardiovascular risk. With over 100 peptide-based drugs now approved globally, peptide therapeutics are no longer niche – they’re central to modern medicine. These therapies are so pervasive that nearly 12% of Americans have used a GLP-1 for weight loss.
The Food and Drug Administration (FDA) approved semaglutide as a 31-amino acid synthetic peptide in 2017, which led to its rapid market adoption. Its effectiveness in controlling blood sugar, reducing body weight and improving cardiovascular outcomes has set a new standard, spurring interest in not only novel GLP-1 analogs but also generic and biosimilar alternatives as key patents expire.
But with this growth comes complexity. GLP-1 drugs, like many therapeutic peptides, are structurally intricate and highly sensitive to degradation, impurity formation and sequence variation. These characteristics demand exceptional analytical control, especially during development, scale-up and regulatory submission. Even trace impurities or structural inconsistencies can compromise efficacy or safety, making quality assurance a top priority.
To meet these demands, drug developers are turning to high-resolution accurate mass spectrometry (HRAM-MS), often in combination with ultra-high performance liquid chromatography (UHPLC). Together, these technologies form the backbone of modern peptide analysis. They give developers a clear read on what’s in the sample, helping them spot impurities, confirm structure and move from discovery to production with confidence.
The analytical challenge: Why peptides are harder to analyze
Despite their therapeutic promise, peptide-based drugs present unique analytical and manufacturing challenges that differentiate them from traditional small-molecule pharmaceuticals. GLP-1 receptor agonists are chemically complex and are produced using advanced biotechnological manufacturing, typically involving recombinant DNA expression, chemical peptide synthesis or a hybrid of both. Each of these methods can introduce variability and impurities throughout the production process, making it essential to monitor the process throughout drug production.
Unlike small molecules with well-defined structures, peptides themselves are also prone to a wide range of peptide-related impurities that persist regardless of production process. These inconsistencies may include:
- Amino acid deletions, insertions, or substitutions
- Isomerization (e.g., D- to L-amino acid changes)
- Chemical modifications to side chains, such as oxidation or deamidation
Small amounts of impurities in peptides can lead to major changes in their biological activity that impact both their effectiveness and their safety profile. The therapeutic range of peptides remains narrow because any structural deviation or dosage variation leads to significant clinical effects.
The high sensitivity of peptides requires precise impurity identification and structural verification methods, which are necessary to satisfy regulatory approval processes and to ensure safety. The FDA and European Medicines Agency (EMA) demand complete knowledge of drug impurities for Abbreviated New Drug Applications (ANDAs), including those that involve generic or follow-on biologic products.
In this environment, conventional analytical tools often fall short. Due to the intricacies outlined, peptides demand high-resolution, highly sensitive and selective techniques capable of distinguishing even minor structural differences. This is where advanced mass spectrometry (MS) becomes indispensable.
The science behind the signal: How MS strengthens GLP-1 therapeutics
The rise of GLP-1 receptor agonists signals a new era in metabolic disease treatment, but their complexity demands an equally advanced analytical approach. HRAM-MS provides not just data, but clarity – enabling a detailed, molecular-level understanding of peptide drugs that is critical for ensuring their safety and efficacy.
The combination of UHPLC with MS, such as Thermo Scientific™ Vanquish UHPLC systems with Thermo Scientific™ Orbitrap MS, provides the necessary sensitivity and resolution to identify chemical composition nuances and impurities, ensuring peptides are ready for therapeutic development. It supports:
- Impurity profiling at extremely low abundance
- Structural verification via peptide mapping and top-down or middle-down analysis
- Disulfide bond and post-translational modifications (PTMs) characterization, which influence folding and bioactivity
- Isomer differentiation, critical in D/L variants that evade traditional detection
MS is also essential in bridging innovation and access. As GLP-1 drug patents begin to expire, biosimilar developers rely on MS to demonstrate molecular comparability with reference products to fulfill rigorous regulatory requirements.
Just as importantly, MS technologies are no longer confined to early R&D. End-to-end workflows that combine MS technology, smart software solutions and integrated compliance tools are designed to move seamlessly from research labs into regulated environments. This means developers can generate high-confidence data at every stage, from candidate selection to batch release.
From discovery to commercialization: MS across the pipeline
The value of MS extends far beyond a single stage of drug development; it plays a critical role across the entire lifecycle of GLP-1 therapeutics. In early R&D, MS enables precise lead optimization and early impurity detection. During formulation development, it supports ingredient-compatibility assessments and helps identify potential degradation pathways. As compounds progress to clinical trials, MS provides bioanalytical support for pharmacokinetic and pharmacodynamic studies, along with long-term stability monitoring. And in scale-up and commercial manufacturing, it ensures batch-to-batch consistency, supports process control and underpins regulatory submissions.
With current systems in place to meet the evolving demands of each phase – from discovery through regulatory-compliant manufacturing – MS-based solutions deliver the data integrity, scalability and regulatory compliance that developers need to bring safe, effective peptide therapeutics to market faster.
What’s next: Advanced analytics for a new era of medicine
GLP-1 receptor agonists are more than just the latest metabolic blockbuster; they represent a broader movement toward biologically complex, precision-driven therapies. As peptide drugs become more central to treating chronic and multifactorial diseases, the importance of and reliance on analytical capabilities will only increase.
High-resolution mass spectrometry platforms, such as Thermo Scientific™ Orbitrap ™ instruments, serve as more than analytical instruments, creating opportunities for groundbreaking discoveries. Organizations that invest in analytical infrastructure during early stages will achieve faster development timelines and enhanced scientific confidence, with lower regulatory risks. Companies that want to extend peptide therapy capabilities need this strategic advantage to succeed in their boundary-pushing initiatives.
Kelly Broster, PhD, is Senior Manager of Pharma & Biopharma Market Development and Collaborations at Thermo Fisher Scientific.
Filed Under: Metabolic disease/endicrinology
